Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Naltrexone treatment for alcoholics: effect on cigarette smoking rates.

Rohsenow DJ, Monti PM, Colby SM, Gulliver SB, Swift RM, Abrams DB.

Nicotine Tob Res. 2003 Apr;5(2):231-6.

PMID:
12745496
2.

A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation.

O'Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R, Makuch R, Jatlow P.

Arch Intern Med. 2006 Mar 27;166(6):667-74.

PMID:
16567607
3.

Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.

Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH; VA Cooperative Study #425 Study Group.

Alcohol Clin Exp Res. 2007 Apr;31(4):555-63.

PMID:
17374034
4.

Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.

Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, Brown RA, Gordon A, Abrams DB, Niaura RS, Asher MK.

Alcohol Clin Exp Res. 2001 Nov;25(11):1634-47.

PMID:
11707638
5.

Early treatment response in alcohol dependence with extended-release naltrexone.

Ciraulo DA, Dong Q, Silverman BL, Gastfriend DR, Pettinati HM.

J Clin Psychiatry. 2008 Feb;69(2):190-5.

PMID:
18348601
6.

Extended naltrexone and broad spectrum treatment or motivational enhancement therapy.

Longabaugh R, Wirtz PW, Gulliver SB, Davidson D.

Psychopharmacology (Berl). 2009 Oct;206(3):367-76. doi: 10.1007/s00213-009-1615-3. Epub 2009 Jul 29.

PMID:
19639303
7.

Effects on smoking cessation: naltrexone combined with a cognitive behavioral treatment based on the community reinforcement approach.

Roozen HG, Van Beers SE, Weevers HJ, Breteler MH, Willemsen MC, Postmus PE, Kerkhof AJ.

Subst Use Misuse. 2006;41(1):45-60.

PMID:
16393735
8.

[Smoking reduction and temporary abstinence: new approaches for smoking cessation].

Le Houezec J, Säwe U.

J Mal Vasc. 2003 Dec;28(5):293-300. Review. French.

PMID:
14978435
9.

Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences.

King A, de Wit H, Riley RC, Cao D, Niaura R, Hatsukami D.

Nicotine Tob Res. 2006 Oct;8(5):671-82.

PMID:
17008194
10.

Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients.

Baltieri DA, Daró FR, Ribeiro PL, Andrade AG.

Drug Alcohol Depend. 2009 Nov 1;105(1-2):33-41. doi: 10.1016/j.drugalcdep.2009.05.025.

PMID:
19595518
11.

Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study.

Caputo F, Addolorato G, Lorenzini F, Domenicali M, Greco G, del RE A, Gasbarrini G, Stefanini GF, Bernardi M.

Drug Alcohol Depend. 2003 May 1;70(1):85-91.

PMID:
12681528
12.

Naltrexone and nicotine patch smoking cessation: a preliminary study.

Krishnan-Sarin S, Meandzija B, O'Malley S.

Nicotine Tob Res. 2003 Dec;5(6):851-7.

PMID:
14750508
13.

Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study.

Caputo F, Addolorato G, Stoppo M, Francini S, Vignoli T, Lorenzini F, Del Re A, Comaschi C, Andreone P, Trevisani F, Bernardi M; Alcohol Treatment Study Group.

Eur Neuropsychopharmacol. 2007 Dec;17(12):781-9. Epub 2007 Jul 3.

PMID:
17611081
15.

Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone.

Ahmadi J, Ashkani H, Ahmadi M, Ahmadi N.

J Subst Abuse Treat. 2003 Apr;24(3):251-5.

PMID:
12810146
16.
17.

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

Robles GI, Singh-Franco D, Ghin HL.

Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Review.

PMID:
18555928
18.

Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.

O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR.

J Clin Psychopharmacol. 2007 Oct;27(5):507-12.

PMID:
17873686
19.

Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.

Adi Y, Juarez-Garcia A, Wang D, Jowett S, Frew E, Day E, Bayliss S, Roberts T, Burls A.

Health Technol Assess. 2007 Feb;11(6):iii-iv, 1-85. Review.

20.

Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial.

Diehl A, Nakovics H, Croissant B, Smolka MN, Batra A, Mann K.

Int J Clin Pharmacol Ther. 2006 Dec;44(12):614-22.

PMID:
17190371

Supplemental Content

Support Center